Therapeutic monoclonal antibodies;Les anticorps monoclonaux thérapeutiques

Annales Pharmaceutiques Francaises

Volumn 64, Issue 5, 2006, Pages 308-311

  Bach, J F ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Autoimmune disease; CD3; Monoclonal antibodies; TNF; Transplantation

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CETUXIMAB; DACLIZUMAB; EDRECOLOMAB; ETANERCEPT; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; PALIVIZUMAB; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; ZANOLIMUMAB;

AUTOIMMUNE DISEASE; CANCER; CONFERENCE PAPER; GRAFT REJECTION; HUMAN; IN VITRO STUDY; NONHUMAN; ORGAN TRANSPLANTATION; RESPIRATORY TRACT INFECTION; TREATMENT INDICATION;

EID: 33749379002     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(06)75323-8     Document Type: Conference Paper

References (6)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7.
2. Cosimi AB, Colvin RB, Burton RC, Rubin RH, Goldstein G, Kung PC et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981; 305: 308-14.
3. Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986; 2: 119-24.
4. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123-7.
5. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-8.
6. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-608.